ReviewBioMed research international2016
Clinically Meaningful Use of Blood Tumor Markers in Oncology.
Review in BioMed research international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 73 citations in OpenAlex.
- Cancer of unknown primary: the evolution of tissue of origin identification in the artificial intelligence era.Biomarker research · 2026Review
- Perioperative Symptom Trajectories and a Risk Prediction Model for Cervical Cancer: A Prospective Longitudinal Study.International journal of women's health · 2026Article
- Significance of Serum Tumor Markers in Esophageal and Gastric Cancers: A Systematic Literature Review.Annals of gastroenterological surgery · 2026Review
- New breast cancer marker BF-09 is overexpressed in tumor extracts and secreted in serum.Biochemistry and biophysics reports · 2025Article
- Serum carbohydrate antigen 153 as a predictor of interstitial lung disease associated with rheumatoid arthritis is positively correlated with serum Krebs von den Lungen-6.BMC pulmonary medicine · 2025Article
- Assessing the diagnostic utility of serum tumor markers for lung cancer detection in patients with interstitial pneumonia.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- αDiagnostics (Basel, Switzerland) · 2024Article
- Cancer of unknown primary and BRAF V600E meeting the BEACON combination: A case report.Molecular and clinical oncology · 2024Article
- Serum Splicing Factor Proline- and Glutamine-Rich Is a Diagnostic Marker for Non-Small-Cell Lung Cancer and Other Solid Cancers.International journal of molecular sciences · 2024Article
- Diagnostic value of serum fibrin degradation complex DR-70 combined with conventional tumor biomarkers in colorectal cancer.The Journal of international medical research · 2024Article
- Novel Tools for Single Comparative and Unified Evaluation of Qualitative and Quantitative Bioassays: SS/PV-ROC and SS-J/PV-PSI Index-ROC Curves with Integrated Concentration Distributions, and SS-J/PV-PSI Index Cut-Off Diagrams.Diagnostics (Basel, Switzerland) · 2024Article
- Review
- Method Comparison and Clinical Performance of Breast Cancer Tumor Markers on Novel Multiplex Immunoassay and Automatized LOCI Technology Platforms.Diagnostics (Basel, Switzerland) · 2023Article
- Longitudinal Evaluation of AFP and CEA External Proficiency Testing Reveals Need for Method Harmonization.Diagnostics (Basel, Switzerland) · 2023Article
- Article
- Proteomic Signature of Extracellular Vesicles Associated with Colorectal Cancer.Molecules (Basel, Switzerland) · 2023Article
- A phase Ib feasibility trial of response adapted neoadjuvant therapy in gastric cancer (RANT-GC).Future oncology (London, England) · 2022Review
- Multiple biomarkers are more accurate than a combination of carbohydrate antigen 125 and human epididymis protein 4 for ovarian cancer screening.Obstetrics & gynecology science · 2022Article
- Utility of tumor-informed circulating tumor DNA in the clinical management of gastrointestinal malignancies.Journal of gastrointestinal oncology · 2021Article
- Protein Kinase A Detection in Human Urine Samples.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Before the introduction of modern imaging techniques and the recent developments in molecular diagnosis, tumor markers (TMs) were among the few available diagnostic tools for the management of cancer patients. Easily obtained from serum or plasma samples, TMs are minimally invasive and convenient, and the associated costs are low. Single TMs were traditionally used but these have come under scrutiny due to their low sensitivity and specificity when used, for example, in a screening setting. However, recent research has shown superior performance using a combination of multiple TMs as a panel for assessment, or as part of validated algorithms that also incorporate other clinical factors. In addition, newer TMs have been discovered that have an increased sensitivity and specificity profile for defined malignancies. The aim of this review is to provide a concise overview of the appropriate uses of both traditional and newer TMs and their roles in diagnosis, prognosis, and the monitoring of patients in current clinical practice. We also look at the future direction of TMs and their integration with other diagnostic modalities and other emerging serum based biomarkers, such as circulating nucleic acids, to ultimately advance diagnostic performance and improve patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.